ALT R&D to Revenue
Altimmune Inc · R&D to Revenue
ALT R&D to Revenue
Latest reported0.00%period ending
ALT Quarterly R&D/Revenue (0.00% → 0.00%)
Latest values, visible window
High-resolution chart · PNG
ALT r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 0% | |
| 0% | |
| 70,803.8462% | |
| 299,200% | |
| 344,720% | |
| 316,540% | |
| 395,620% | |
| 396,060% | |
| 423,100% | |
| 429,740% | |
| 45,700% | |
| 5,079.558% | |
| 220,883.3333% | |
| 82,138.0952% | |
| -17,435.4545% | |
| 1,013,100% | |
| 199,912.5% | |
| 47,200% | |
| 615.9597% | |
| 18,484.8101% | |
| 9,687.5912% | |
| 1,417.4224% | |
| 387.0173% | |
| 580.0554% | |
| 2,299.5319% | |
| 324.8317% | |
| 672.6437% | |
| 1,355.5893% | |
| 181.122% | |
| 108.8672% | |
| 118.3895% | |
| 179.4996% | |
| 203.5034% | |
| 116,382.5638% | |
| 158.7819% | |
| 128.6069% | |
| 106,414.115% | |
| 90.2653% | |
| 127.4859% | |
| 124.4301% | |
| 54.1471% | |
| 102.3304% | |
| 92.4981% | |
| 97.4067% | |
| 106.3465% | |
| 22.8276% | |
| 98.079% | |
| 179.6381% | |
| 64.8464% | |
| 91.5692% | |
| 112.1462% | |
| 73.2878% | |
| 79.2137% | |
| 80.8241% | |
| 78.9362% | |
| 76.7402% | |
| 77.8638% | |
| 76.5217% | |
| 72.6186% | |
| 92.8551% | |
| 93.0821% | |
| 91.837% | |
| 55.5981% | |
| 98.8561% | |
| 124.2859% | |
| 158.9061% | |
| 104.54% | |
| 111.4107% | |
| 117.2641% | |
| 103.1406% | |
| 97.3814% | |
| 88.1786% | |
| 102.4723% | |
| 100.631% | |
| 97.6872% | |
| 108.161% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |